YAP/TEAD inhibitor VT3989 in solid tumors: a phase 1/2 trial – Nature

Written by

admin

in

  1. YAP/TEAD inhibitor VT3989 in solid tumors: a phase 1/2 trial  Nature
  2. ESMO: Vivace tunes up for phase 3 after midstage mesothelioma trial hits high note  Fierce Biotech
  3. ESMO25: Vivace preps Phase III move for Hippo-targeting mesothelioma drug  

Continue Reading

More posts